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Abstract 
Purpose: Phlebitis caused by intravenous infusion of antineoplastic agents is one of the 
critical problems when anticancer therapy is prolonged. We have already reported that both 
rapid infusion and dilution of the injection solution were effective methods for reducing 
phlebitis caused by vinorelbine (VNR) in rabbits. The aim of this study was to explore other 
practical methods for preventing phlebitis caused by VNR and doxorubicin (DXR) in a rabbit 
model. VNR is often used with cisplatin, and dexamethasone (DEX) has been 
co-administered for prevention of cisplatin-induced nausea. DXR is used with prednisolone 
(PSL) in the CHOP regimen for the treatment of non-Hodgkin’s lymphoma. Therefore, the 
present study investigated the prevention of phlebitis due to VNR with DEX and that due to 
DXR with PSL. 
Methods: VNR and DXR were diluted with normal saline to prepare test solutions at 
concentrations of 0.6 mg/mL and 1.4 mg/mL, respectively. Each test solution was infused into 
the auricular veins of rabbits. Two days after VNR infusion and three days after DXR infu-
sion, the veins were evaluated histopathologically. The effect of DEX on VNR-induced 
phlebitis was evaluated by infusion of DEX before or after VNR. The effect of PSL on 
DXR-induced phlebitis was similarly evaluated by co-infusion of PSL. 
Results: The histopathological features of phlebitis caused by the antineoplastic agents dif-
fered between VNR and DXR: VNR did not cause the loss of venous endothelial cells, but 
caused inflammatory cell infiltration, edema, and epidermal degeneration. In contrast, DXR 
caused the loss of venous endothelial cells and chrondrocyte necrosis. Pre-treatment and 
post-treatment with DEX significantly decreased VNR-induced phlebitis compared with the 
control group and pre-treatment was particularly effective. Co-infusion of PSL also signifi-
cantly decreased phlebitis caused by DXR, but its effect was less marked. 
Conclusion: The present findings suggested that pre-treatment with DEX may be a useful 
method for preventing phlebitis due to VNR, and that co-infusion of PSL has the potential to 
prevent phlebitis caused by DXR. 
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Introduction 
Chemotherapy, including novel antineoplastic 
agents, is becoming increasingly effective for cancer 
and is performed widely, but adverse drug reactions 
are still a critical problem. The completion of chemo-
therapy regimens is an important factor that deter-
mines the prognosis of patients, but it is often the case 
that treatment is discontinued due to adverse drug 
reactions. Among such reactions, phlebitis induced 
by intravenous infusion of antineoplastic agents re-
duces the completion of chemotherapy. The causative 
factors of phlebitis include the pH and osmotic pres-
sure of the solution, the size of the vein used, the size 
and material of the catheter, and the infusion periods 
[1]. A number of methods for avoiding phlebitis have 
been reported [2, 3], but none are completely effec-
tive. Thus, there is an urgent need to develop new 
methods to prevent and alleviate phlebitis. We al-
ready showed that rapid infusion and dilution of 
VNR are effective for reducing phlebitis [4]. In this 
study, we investigated other practical methods for 
preventing phlebitis. 
VNR is a semi-synthetic vinca alkaloid derived 
from vinblastine that is used to treat non-small cell 
lung cancer and breast cancer, and a high incidence of 
phlebitis (16-33%) after a 6-min infusion of VNR has 
been reported [5-7]. VNR is often used together with 
cisplatin and DEX, which is given to prevent nausea 
and vomiting caused by cisplatin. DXR is an anthra-
cycline antineoplastic agent that is widely used to 
treat non-Hodgkin’s lymphoma as one component of 
the CHOP regimen, along with PSL. It is also known 
to cause phlebitis after intravenous infusion [3]. 
Corticosteroids have been suggested to be effec-
tive for prevention of phlebitis, due to their 
anti-inflammatory action [8-11]. Tononi et al. reported 
that post-treatment with DEX reduced phlebitis 
caused by VNR [12], although they did not show the 
actual data. Thus, to demonstrate that corticosteroids 
can prevent the development of phlebitis after 
anti-cancer chemotherapy, we investigated the effects 
of DEX and PSL on VNR- and DXR-induced phlebi-
tis, respectively, in a rabbit model. 
Materials and Methods 
Animals 
Male Japanese white rabbits (Std; JW, Japan 
SLC, Inc., Shizuoka, Japan) weighing from 2.3 to 3.5 
kg were housed in individual cages in an animal 
room maintained at 23 ± 3 °C and 55 ± 10 % relative 
humidity with ventilation 13-16 times/hr and a 12-hr 
light-dark cycle. The rabbits were allowed free access 
to diet and water, except during infusion with the test 
solutions. This study was approved by the animal 
experiments committee of Mukogawa Women’s 
University. 
Drugs 
Navelbine® Injection (VNR) and Adriacin® Injec-
tion (DXR) were kindly provided by Kyowa Hakko 
Kirin Co. (Tokyo, Japan). A 10 mg/mL vial of VNR 
was diluted with normal saline (Otsuka Normal Sa-
line, Otsuka Pharmaceutical Factory, Inc., Tokushima, 
Japan) to provide a 0.6 mg/mL solution, while a 10 
mg vial of DXR was dissolved and diluted with nor-
mal saline to provide a 1.4 mg/mL solution. DEX 
(Decadron®, 8 mg Banyu Pharmaceutical Co., Tokyo, 
Japan) and PSL (Predonine®, 20mg Shionogi & Co., 
Osaka, Japan) were used to prevent VNR- and 
DXR-induced phlebitis, respectively, after being pre-
pared at a concentration of 0.8 mg/mL and 1 mg/mL 
in normal saline. 
The dose of VNR and DXR were determined at 3 
and 4 times the clinical dose from the preliminary 
experiments as the highest dose that caused phlebitis 
in all animals without producing other adverse 
events. As a result, DEX and PSL were administered 
at 3 and 4 times the clinical dose, respectively. 
Experimental procedure 
The effects of rapid infusion and dilution of the 
injection solution on phlebitis caused by VNR was 
evaluated in a rabbit model, as reported elsewhere 
[4]. Briefly, test solutions of VNR or DXR were in-
fused into both ears of a rabbit to compare different 
infusion conditions. The rabbits were euthanized 
with sodium pentobarbital (Nembutal®, Dainippon 
Sumitomo Pharmaceutical Co., Osaka, Japan) at 2 
days after VNR infusion or 3 days after DXR infusion. 
Two samples of the ear vein were obtained, including 
the region at 3-10 mm (proximal) and that at 20-30 
mm (distal) from the catheter tip, and these were 
fixed in phosphate-buffered 10% formalin (Figure 1). 
Cross-sections of the ear vein were cut and stained 
with hematoxylin and eosin. Histopathological 
evaluation was performed by a single observer who 
was blinded to the treatment of the specimen, and the 
findings were graded with respect to loss of venous 
endothelial cells, inflammatory cell infiltration, 
edema, and thrombus, while adding epidermal de-
generation [13] that is not included in the criteria of 
Kuwahara [4]. 
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Figure 1. Sites of histopathological examination. Two regions of the ear vein, one located at 3-10 mm from the catheter tip 
(proximal region) and the other located at 20-30 mm from it (distal region), were sampled at 2 or 3 days after VNR or DXR 
infusion, respectively. 
 
Effect of DEX on VNR-induced phlebitis 
A 0.6-mg/mL solution of VNR was infused over 
30 min at 5 mL/kg/hr into the ear vein. To clarify the 
effect of DEX on phlebitis caused by VNR infusion, a 
0.8-mg/mL solution of DEX was infused for 15 min at 
5 mL/kg/hr just before (pre-treatment) or just after 
(post-treatment) the infusion of VNR. In the control 
group, normal saline was infused before and after 
VNR. Tononi et al. reported that post-treatment with 
DEX reduced phlebitis caused by VNR, so we tried to 
clarify the difference in the effect of DEX administra-
tion before VNR or after VNR. 
Effect of PSL on DXR-induced phlebitis 
A 1.4 mg/mL solution of DXR was infused for 
120 min at 2 mL/kg/hr with 1-mg/mL of PSL or 
normal saline (the control group) at 2 mL/kg/hr into 
the ear vein. In our preliminary experiments, 
co-administration of PSL exhibited a superior effect 
compared with pretreatment, so we investigated the 
efficacy of PSL co-administration in this study. 
Statistical analysis 
The grade of each histopathological finding was 
analyzed by the Wilcoxon rank sum test in each ex-
periment, and p<0.05 was considered to indicate a 
significant difference. 
Results 
Effect of DEX of VNR-induced phlebitis 
Figure 2 shows a representative photomicro-
graph of an ear vein after VNR infusion. Table 1 
summarizes the histopathological findings after infu-
sion of VNR with or without pre-treatment or 
post-treatment with DEX. Infusion of a 0.6-mg/mL 
solution of VNR for 30 min at 5 mL/kg/hr (the con-
trol group) caused slight loss of venous endothelial 
cells (Grade 1) in the proximal part of the vein in 2 
out of 8 animals. In addition, there was inflammatory 
cell infiltration (Grades 1-3) in the proximal part of 
the vein in all 8 animals and in the distal part of the 
vein in 7 of the 8 animals. Edema (Grades 1-3) was 
found in the proximal part of the vein in 6 of the 8 
animals and in the distal part of the vein in 7 of the 8 
animals. Epidermal degeneration (Grades 1-3) was 
found in both the proximal and distal parts of the 
vein in all 8 animals. When infusion of DEX was done 
before VNR (pre-treatment with DEX), there was 
slight loss of venous endothelial cells (Grade 1) at the 
distal region of the vein in 2 of the 8 animals, in-
flammatory cell infiltration (Grades 1-2) at the 
proximal region in 2 animals and at the distal region 
in 1 animal, slight edema (Grade 1) at the proximal 
region in 1 animal, and epidermal degeneration 
(Grades 1-2) at both the proximal and distal regions 
in all 8 animals. When DEX was infused after VNR 
(post-treatment with DEX), there was inflammatory 
cell infiltration (Grades 1-3) at the proximal region of 
the vein in 4 animas and at the distal region in 3 of 
the 8 animals, edema (Grade 3) at the proximal region 
in 1 animal and edema (Grade 2) at the proximal re-
gion in 2 animals, and epidermal degeneration 
(Grades 1-3) at the proximal in all 8 animals and at 
the distal regions in 6 animals. With regard to the loss Int. J. Med. Sci. 2009, 6 
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of venous endothelial cells, neither pre-treatment nor 
post-treatment with DEX led to a significant differ-
ence. With regard to inflammatory cell infiltration, 
edema, and epidermal degeneration, pre-treatment 
with DEX reduced these changes significantly at both 
the proximal and distal regions of the vein. However, 
post-treatment with DEX had a weaker inhibitory 
effect on VNR-induced phlebitis than the 
pre-treatment. 
 
 
Figure 2. Typical photomicrographs of an ear vein after VNR infusion. A 0.6-mg/mL solution of VNR was infused into the 
ear vein for 30 min at 5 mL/kg/hr, and the vein was subjected to pathological examination after 2 days. 
 
Table 1 Effect of pre-treatment and post-treatment with DEX on the histopathological grade in 8 rabbits at 2 days after 
VNR infusion.  
 Loss  of 
venous 
endothelial 
cells 
Inflammatory 
cell infiltra-
tion 
Edema Thrombus  Epidermal 
degeneration
Region 
Grade 0  1  2  3 
p 
value 
0 1 2 3 
p 
value
0 1 2 3 
p 
value 
0 1 2 3 
p 
value 
0 1 2 3 
p 
value 
Control  6 2 0 0   0 1 3 4   2 3 2 1   8 0 0 0   0  2  4  2   
Pre-treatment  with  DEX 8 0 0 0 N.S.  6 1 1 0 <0.01 7 1 0 0 <0.05 8 0 0 0 N.S.  0  7  1  0  <0.05 
Proximal 
Post-treatment  with  DEX  8 0 0 0 N.S.  4 3 0 1 <0.01 7 0 0 1 N.S.  8 0 0 0 N.S.  0  5  1  2  N.S. 
Control  8 0 0 0   1 2 3 2   1 2 2 3   8 0 0 0   0  3  3  2   
Pre-treatment  with  DEX 6 2 0 0 N.S.  7 1 0 0 <0.01 8 0 0 0 <0.01 8 0 0 0 N.S.  0  8  0  0  <0.05 
Distal 
Post-treatment  with  DEX  8 0 0 0 N.S.  5 0 1 2 N.S.  6 0 2 0 <0.05 8 0 0 0 N.S.  2  4  1  1  N.S. 
Numbers in the table represent the number of observations. P values show a significant difference from control. N.S.; not significant. 
 
Effect of PSL on DXR-induced phlebitis 
Figure 3 shows representative photomicrograph 
of an ear vein after DXR infusion. Table 2 summarizes 
the histopathological findings obtained after infusion 
of DXR with PSL or normal saline (the control group). 
Infusion of a 1.4-mg/mL solution of DXR for 120 min 
at 2 mL/kg/hr with normal saline (the control group) 
at 2 mL/kg/hr caused the loss of venous endothelial 
cells (Grades 1-2) at the proximal region of the vein in 
3 animals and at the distal region in 5 out of 7 ani-
mals, inflammatory cell infiltration (Grades 1-2) at the 
proximal and distal regions in all 7 animals, and 
edema (Grades 1-3) at the proximal and distal regions 
in all 7 animals. No thrombus or epidermal degenera-
tion was found in any of the animals. In addition, Int. J. Med. Sci. 2009, 6 
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chrondrocyte necrosis was observed after treatment 
with DXR (Figure 3). 
With regard to the loss of venous endothelial 
cells and inflammatory cell infiltration, co-infusion of 
PSL tended to reduce the effects of DXR, although the 
improvement was not statistically significant. A sig-
nificant difference was only found for edema of the 
p r o x i m a l  p a r t  o f  t h e  v e i n .  I t  w a s  s u g g e s t e d  t h a t  
co-infusion of PSL could be tried as a preventive 
method for DXR-induced phlebitis, but with limited 
efficacy. 
 
 
 
 
 
Figure 3. Typical photomicrographs of an ear vein after DXR infusion. A 1.4-mg/mL solution of DXR was infused into the 
ear vein for 60 min at 2 mL/kg/hr, and the vein was subjected to pathological examination after 3 days. 
 
 
Table 2 Effect of co-infusion of PSL on the histopathological grade in 7 rabbits at 3 days after DXR infusion. 
  Loss of ve-
nous endo-
thelial cells 
Inflammatory 
cell infiltra-
tion 
Edema Thrombus  Epidermal  de-
generation 
Region 
Grade  0 1 2 3 
p 
value 
0 1 2 3 
p 
value
0 1 2 3 
p 
value
0 1 2 3 
p 
value 
0 1 2 3 
p 
value 
with  normal  saline  4 3 0 0  0 3 4 0  0 1 3 3  7 0 0 0  7  0  0  0  Proximal 
with  PSL  6 1 0 0 
N.S. 
0 5 1 1 
N.S. 
0 4 3 0 
<0.05
7 0 0 0 
N.S. 
7 0 0 0 
N.S. 
with  normal  saline  2 4 1 0  0 3 4 0  0 1 2 4  7 0 0 0  7  0  0  0  Distal 
with  PSL  5 1 1 0 
N.S. 
1 2 4 0 
N.S. 
1 1 2 3 
N.S. 
7 0 0 0 
N.S. 
7 0 0 0 
N.S. 
Numbers in the table represent the number of observations. P values indicate a significant difference between the normal saline and PSL 
groups. N.S.; not significant. 
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Discussion 
The histopathological features of phlebitis dif-
fered between VNR and DXR infusion in the present 
rabbit model. VNR did not cause the loss of venous 
endothelial cells, which is a common finding in phle-
bitis [14], but caused inflammatory cell infiltration, 
edema, and epidermal degeneration. DXR (an an-
thracycline anticancer agent) caused the loss of ve-
nous endothelial cells, and also produced chrondro-
cyte necrosis. Epirubicin was reported to have the 
same effects on chrondrocyte necrosis [15], suggest-
ing that these findings may be characteristic of phle-
bitis caused by anthracyclines. The chrondrocyte ne-
crosis is peculiar to animal experiments using rabbit 
auricular vein and therefore is not directly reflected 
in patients, but they suggested that this finding may 
be a useful and specific index to evaluate perivascular 
tissue damages caused by this kind of agents [15]. 
We have already shown that both rapid admini-
stration and dilution of the infusion solution is effec-
tive for preventing VNR-induced phlebitis [4]. In ad-
dition, the present study suggested that 
pre-treatment and post-treatments with DEX were 
also effective methods. There have been a few reports 
that administration of steroids is useful for prevent-
ing irritation and phlebitis caused by intravenous 
infusion of hypertonic solutions in animals [16]. As 
mentioned above, there has only been one report that 
DEX can reduce phlebitis after the infusion of VNR, 
but without any evidence to support this claim [12]. 
Therefore, this is the first study to show that treat-
ment with DEX is effective for preventing phlebitis 
caused by the infusion of VNR. In addition, our data 
suggested that the pre-treatment with DEX was more 
effective than post-treatment. Although the underly-
ing mechanism by which DEX prevents phlebitis is 
not clear, it might be related to the well-known 
anti-inflammatory effects of steroids. However, fur-
ther studies will be needed to determine this. 
We also investigated the effect of PSL on 
DXR-induced phlebitis. Co-infusion of PSL caused a 
decrease in the grade of phlebitis due to DXR. Both 
DXR and PSL are used to treat non-Hodgkin’s lym-
phoma in the CHOP regimen, so co-infusion of PSL 
could be a practical method for preventing 
DXR-induced phlebitis, albeit with minimal efficacy. 
In conclusion, the histological features of phlebi-
tis caused by antineoplastic agents differ between 
VNR and DXR. Our data suggested that 
pre-treatment with DEX was a useful preventive 
method for VNR-induced phlebitis, and that 
co-infusion of PSL could potentially prevent phlebitis 
caused by DXR. 
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